Ontology highlight
ABSTRACT:
SUBMITTER: Karakashev S
PROVIDER: S-EPMC5745042 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature
Cell reports 20171201 12
PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment of BRCA-proficient ovarian cancer cells with the BET inhibitor JQ1 downregulated the G2-M cell-cycle checkpoint regulator WEE1 and the DNA-damage response factor TOPBP1. Combining PARP inhibitor O ...[more]